Search

Psychiatric Pharmacogenomics is a book written to help clinicians to use pharmacogenomic testing to improve the pharmacotherapy that they provide for their patients. It is designed to teach clinicians how to order pharmacogenomic tests and interpret the results. Clinical examples are used to underscore the specific indications for pharmacogenomic testing and to clarify the clinical usefulness of identifying atypical genotypes that result in problematic responses to medication. The first section of the book begins with a basic review of molecular genetics. Additionally, the book also includes an extensive glossary of technical terms associated with molecular genetics and pharmacogenomics. The clinical utility of pharmacogenomic testing is demonstrated throughout the book by describing the implications of genetic variations for the care of individual patients. The second section of the book is organized into fourteen chapters that each focus on the clinical implications of testing for specific genes for which variants have been associated with either therapeutic response or side effects of psychotropic medications. Each of these chapters is structured in the same manner and involves a description of the gene and its significant variants. Each chapter also includes one or more clinical vignettes. The third section of the book discusses the clinical usefulness of pharmacogenomic testing, ethical issues associated with pharmacogenomic testing, and provides predictions for the future development of more sophisticated pharmacogenomic testing.

With examinations of 19 new psychiatric drugs, 19 new forms of previously available drugs, and a host of new medical agents, this third edition of the Clinical Manual of Psychopharmacology in the Medically Ill has been updated to include medical and psychiatric drugs that have become available since the publication of the second edition in 2017, as well as recent relevant randomized controlled trials, systematic reviews, and meta-analyses. Boasting all the rigor that characterized the preceding editions, every chapter in this new volume has been reviewed and revised by experts—including 11 new authors. For 15 categories of medical disorders and specialty areas that include cardiovascular disorders, oncology, obstetrics and gynecology, and substance use disorders, the book examines • Key differential diagnostic considerations • The evidence for the efficacy of psychiatric drugs in each disorder • Disease-specific side effects of psychiatric drugs • Neuropsychiatric side effects of drugs for each medical disorder • Disease-specific alterations in pharmacokinetics • Drug-drug interactions Patients with medical and psychiatric comorbidity have more functional impairment, disability days, emergency department use, and rehospitalization, as well as higher medical care costs. By examining the intersection of psychiatric and medical illness, and offering easily referenced key points for each chapter, this new edition prepares both mental health practitioners and primary care physicians and internists to more safely and effectively work with patients who have psychiatric and medical illness.

The book has been practically rewritten with varying degrees of changes in chapters though some would seem to be similar to the last edition. Each chapter begins with an overview and the drugs part has a table on monitoring protocols. We have attempted to make the section easy to read and practical apart from redoing almost all the diagrams that depict the mechanism of action of drugs. We have added a drug overview which can serve as a “birds eye” view of the drug for the busy reader. Also, we have changed the headings into easy to read sections with color coded text highlighting aspects of interest like “Uses” which is in green font. A special “Patient Advise” box has been added.

This text covers the key information necessary to pass Paper A of the postgraduate examination to become a member of the Royal College of Psychiatrists (MRCPsych). It emphasises memory aids in the forms of diagrams or tables, a novel presentation of these materials, providing a quick and portable source for pre-exam revision and visual memory aids and prompts.

The new edition of Clinical Manual of Psychopharmacology in the Medically Ill continues the legacy and builds on the success of the first edition by offering a thoroughly up-to-date, comprehensive, and practical guide to the prescription of psychotropic medications in patients with medical illness. The book addresses the prevalence of psychiatric illness in patients with serious medical illness, the complications that may arise, and the implications for psychopharmacological treatment. There is increasing recognition that patients with medical and psychiatric comorbidity have more functional impairment, disability days, emergency department use, rehospitalization, and other medical care costs than do those without such comorbidity. As a result, health care systems have been incentivized to develop new and innovative models of population-based care that integrate medical and psychiatric care in an effort to increase quality and prevention while decreasing use of expensive services such as emergency department visits and hospitalizations. The book is a valuable guide for clinicians across a range of specialties operating in this new, more demanding health care environment. The manual addresses critically important topics through the use of a variety of user-friendly features: • Psychiatric drugs that have become available since the first edition, as well as all recent relevant randomized controlled trials, systematic reviews, and meta-analyses, are covered thoroughly.• Each chapter addresses key differential diagnostic considerations and adverse neuropsychiatric side effects of disease-specific medications.• Disease-specific pharmacokinetic principles in drug prescribing, including interactions between psychotropic drugs and disease-specific drugs, are also addressed.• Key summary points pertaining to psychotropic prescribing in the specific medical disease(s) or specialty area covered are included at the end of each chapter, and a multitude of useful tables summarizing the most important information are provided as well.• Chapters are heavily referenced with source information should readers wish to expand their knowledge in a specific area. The chapter authors were selected for their expertise in each area, then the text was edited for consistency, clarity, and maximum utility. Clinical Manual of Psychopharmacology in the Medically Ill is a rigorous and illuminating guide to this vital topic, and clinicians from a variety of specialties will find it indispensable.

In the 7 years since the first edition of Clinical Manual of Geriatric Psychopharmacology was published, dozens of new drugs have been released, and older medications have been marketed in different formulations. In addition, research on pharmacokinetics, pharmacodynamics and mechanism of action, potential interactions, and other critical topics has proceeded apace, rendering much of the information in existing guides obsolete. This new volume is both comprehensive and completely up to date, offering information unavailable elsewhere. • New drugs covered include asenapine, paliperidone, iloperidone, lurasidone, desvenlafaxine, vilazodone, long-acting trazodone, milnacipran, armodafinil, extended-release valproate, rotigotine transdermal, tetrabenazine, dextromethorphan, long-acting gabapentin, and transdermal buprenorphine.• Each chapter has a standardized format, with topics including pharmacokinetics, pharmacodynamics and mechanism of action, drug interactions, clinical use (which addresses choice of drug, alternative formulations/routes, pre-treatment evaluation, dose and dose titration, PRN use, monitoring treatment, drug levels, managing treatment resistance, switching drugs, duration of treatment, discontinuation, and overdose), adverse effects, and treatment of selected syndromes and disorders.• Dozens of tables, boxes, and figures organize and present complex material, such as practice guidelines, in a straightforward manner that is easy to understand and apply, and the concise, bulleted text facilitates reading and comprehension in the clinical setting.•'Specific Drug Summaries'-- one-page summaries of prescribing information for individual drugs -- provide fast access to critical information in a simple format. Designed for residents, fellows, and all clinicians in psychiatry and medicine who diagnose and treat psychiatric and neuropsychiatric conditions affecting geriatric patients, this clinical reference can be used across all treatment settings (inpatient, outpatient, day hospital, consultation, and nursing home). Meticulously referenced and grounded in the latest research, Clinical Manual of Geriatric Psychopharmacology, Second Edition, is the definitive guide to psychotropic use in elderly patients. Clinicians can rely confidently on its up-to-date coverage and authoritative counsel.

A comprehensive yet practical guide to the prescription of psychotropic medications in patients with medical illness, Clinical Manual of Psychopharmacology in the Medically Ill is designed to be useful to clinicians practicing in a broad range of specialties, from the psychosomatic medicine specialist caring for a delirious patient with cancer to the general medical practitioner prescribing an antidepressant to a diabetic patient who recently had a myocardial infarction. This manual • Provides useful psychotropic prescribing protocols that can be employed by primary care physicians, psychiatrists, and other medical professionals.• Reviews fundamental principles of psychotropic drug prescribing across medical specialties.• Educates clinicians regarding the growing evidence base supporting the safety and efficacy of psychopharmacological treatments for a diverse range of psychiatric problems in medically ill patients.• Provides clinically relevant information concerning psychopharmacology in the medically ill, including pharmacokinetic and pharmacodynamic principles, drug-drug interactions, and organ system disease-specific issues. Clinical Manual of Psychopharmacology in the Medically Ill is divided into two sections. The first supplies fundamental background information for prescribing psychotropics across medical disease states, including discussion of pharmacodynamics and pharmacokinetics, drug-drug interaction principles, major systemic adverse effects of psychotropic drugs, and alternate routes of psychotropic drug administration. The second section addresses psychopharmacological treatment in specific organ system diseases, such as renal and cardiovascular disease, as well as other relevant subspecialty areas, such as critical care, organ transplantation, pain, and substance use disorders. Authored by experts in the field, chapters contain the following: • Key differential diagnostic considerations, including adverse neuropsychiatric side effects of disease-specific medications• Disease-specific pharmacokinetic principles in drug prescribing, including interactions between psychotropic drugs and disease-specific drugs• Useful tables summarizing information on adverse neuropsychiatric side effects of disease-specific medications, adverse disease-specific side effects of psychotropic drugs, and drug-drug interactions• Extensive referencing of source material to allow readers to expand their knowledge in specific areas This manual, beyond serving as a clinical guide, should become a mainstay of curricula in general psychiatric residency programs, psychosomatic medicine fellowships, and nonpsychiatric residency training programs that prepare physicians to provide safe and effective psychopharmacological treatment for patients with medical illness.

In recent years, there have been major developments in the fields of pharmacogenetics and pharmacogenomics, with the potential to make drug treatments in psychiatric medicine more effective. However, improvements in drug efficacy and tolerability, as well as finding the optimal dosage, can only be realized if in vivo mechanisms of drug action and ADME (absorption, distribution, metabolism, excretion) processes (pharmacokinetics) of psychopharmacological agents are better understood. In this volume, current progress and perspectives in pharmacogenetic testing of drug-metabolizing enzymes, drug transporters and other drug targets involved in the response to psychotropic agents are described extensively. This provides a timely overview of what has been achieved in the area of psychiatric pharmacogenomics alongside some promising directions and perspectives for future research. Psychiatrists, general medical doctors as well as pharmacologists and clinical pharmacologists will find new insights into the development and applications of pharmacogenomics in psychiatry.

Solomon Snyder has been instrumental in the establishment of modern psychopharmacology -- as a pioneer in the identification of receptors for neurotransmitters and drugs and in the explanation of the actions of psychotropic agents. Science and Psychiatry is a collection of some of his best scientific papers, publications ranging over forty years that represent important advances in psychopharmacology and molecular biology. Audacious and unanticipated when they first appeared, these papers opened up new areas of understanding and revolutionized the modern study of the brain. Republished here, they show why fundamental research into the'messengers of the mind'is as essential for clinicians as for researchers.Many of these papers have clear clinical relevance, offering insight into modern neuroscience to help make sense of the bewildering array of available psychotropic medications and point the way toward more effective and safer agents. Others describe the underpinnings of psychopharmacology that practitioners need to know, especially regarding the role of receptors in drug action. Each of the nine groups of research articles is accompanied by a commentary by a well-known authority, putting the discoveries in perspective and providing a broad overview of subjects ranging from characterization of the enkephalins to serotonin receptor subtypes. The final set of papers focuses on apoptosis, the general process of cell suicide, where Snyder's work with bilirubin holds promise for treating neurodegenerative disorders. And in a closing piece,'The Audacity Principle in Science,'Snyder speculates about factors conducive to creativity and efficacy in scientific discovery.The articles particularly describe four groups of extraordinary discoveries for which Snyder is widely recognized: • Identification of opiate receptors, providing keys to understanding pain perception• Characterization of the IP3 receptor, exploring its role as a target for lithium treatment in manic-depressive disorders• Establishment of nitric oxide as a transmitter in the brain, radically transforming conceptualizations of neurotransmission• Discovery that D-serine is the normal stimulus for the glycine site of the NMDA receptor, providing new insight into the regulation of the receptor important for learning and memory Hailed as one of the preeminent scientists of the past twenty years, Snyder is a consummate researcher who confesses to remaining obsessed with the need to'think thoughts no one else has thought before.'Science and Psychiatry clearly shows how that urge accounts for the diversity of challenges he has taken on as it conveys the origins of modern psychopharmacologic practice.

What do clinicians need to know to safely and effectively prescribe psychotropic medications to elderly patients? Understanding the complex pharmacological changes that occur with aging is critical to informed prescribing -- yet much of today's practice in geriatric prescribing continues to be based on anecdotal evidence and case report data, instead of on much-needed controlled research studies. Navigating the vast database in geriatric psychopharmacology is a daunting task at best, leaving many clinicians overwhelmed and confused -- and opening the door to potentially dangerous consequences for some of our most fragile patients.Clinicians can now turn to this definitive handbook for answers. Here, three experienced pharmacologists provide a truly practical'how to'guide to prescribing medications in the geriatric population, drawing on their own clinical experience and their reading of the literature in geriatric psychopharmacology.Unlike other hardcover-only references in this field, this concise handbook is replete with valuable advice (e.g., drug dosing, titration) for day-to-day clinical practice, including strategies for improving compliance among the elderly. Also included are unique quick-reference summaries of prescribing data on selected drugs in each class. • The introduction focuses on the essentials of geriatric pharmacokinetics and a general approach to geriatric prescribing, offering guidelines on how to improve compliance in the elderly.• The next four chapters each cover a major psychotropic class of medications -- antipsychotics, antidepressants, mood stabilizers, and anxiolytic and sedative-hypnotic medications -- including information about pharmacology (baseline labs), clinical use (drug titration), side effects, and treatment. Here, at the end of each of these chapters, you'll find the unique'quick-reference'summaries of prescribing data for selected drugs in each class.• Also detailed here are three critical areas of geriatric psychopharmacology -- treatment of substance-related disorders, movement disorders, and dementias and other cognitive syndromes -- areas that do not fit well into the traditional organization of psychopharmacology books and that therefore have seldom been the subject of in-depth discussions elsewhere in the literature. Written for residents, fellows, and clinicians in psychiatry and medicine who diagnose and treat psychiatric and neuropsychiatric conditions that can affect geriatric patients, this clinical reference can be used across all treatment settings for the elderly (inpatient, outpatient, day hospital, consultation, and nursing homes). Geriatric and general psychiatrists, geriatric medical specialists, internists and family practitioners, medical students and residents, and case managers and social workers will all rely on this handy guide for the critical information needed to provide optimal care for our fast-growing population of elderly patients.

Ethnicity and Psychopharmacology addresses the most relevant theoretical and clinical aspects of ethnopsychopharmacology, with the aim of advancing this growing field well into the twenty-first century. Detailed are the pharmacogenetic, pharmacokinetic, and pharmacodynamic mechanisms involved in differing responses to drug treatment among various ethnic groups living in the United States. Readers will learn an integrative approach in which ethnic and cultural diversity and biological diversity are taken into account and treatment is tailored to specific individual characteristics.Dr. Ruiz's extensive research experience and years of leadership in public psychiatry along with his distinguished panel of contributors combine to make this book an authoritative resource. Psychiatric practitioners, educators, and investigators, as well as other mental health professionals, primary care physicians and medical students, will gain a better understanding of treating patients from different cultures.

Recent Advances In Neuropsychopharmacology contains selected papers from the 12th Congress of the Collegium Internationale Neuro-Psychopharmacologicum held in Gõteborg, Sweden, 22-26 June 1980. The 47 papers in the volume are organized into six parts. The papers in Part I deal with the subject of psychostimulants in psychiatric research. Topics covered include the effect of chronic d-amphetamine and chronic apomorphine treatment on non-human primate social and solitary behavior; and the behavioral effects of dopamine agonists. Part II assesses the prescription of psychotropic drugs by general practitioners. Part III examines blood platelets as a model system for central monoaminergic neurons. Part IV focuses on anxiety pathways in the brain. Part V considers prospects for a biochemical classification system in psychiatry. Part VI presents pharmacokinetic studies of psychotropic drugs. Part VI contains two papers on the renal function and renal histology of lithium patients on maintenance lithium therapy and pre-lithium patients; and the treatment of refractory schizophrenia.

This book is a thorough revision of one of the most comprehensive reference volumes for persons working in the area of aging and mental health. The thrust of the work is interdisciplinary, and discusses research on both clinical and practical issues in aging and mental health.The multidisciplinary nature of this book and the inclusion of subject matter from the professional as well as research realm result in a level of comprehensiveness which is distinct in the field of mental health and agingEach chapter contains a comprehensive bibliography, the compilation of which represents a definitive reference source in the fieldThe chapters review state-of-the-art research in the biological, behavioral, and social sciences and represent the cutting-edge of current practice in psychiatry, neurology, social work, nursing, psychology, and pharmacology, among other professionsThe compilation of prevalence data is a much-needed addition to the current literatureThe multidisciplinary nature of this book and the inclusion of both clinical and practical issues makes the book distinctively comprehensive